Carnegie acted as joint lead manager and joint book-runner in the rights issue of SEK 637 million. Swedish Orphan Biovitrum is a leading European specialty pharmaceutical company.June, 2011.
Healthcare
Rights issue in Swedish Orphan Biovitrum (SE) — SEK 637 million
June 2011